This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Rising P/E: An Ignored Trick to Pick 5 Winning Stocks
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Veeva Systems (VEEV) Boosts Portfolio of Cloud-Based Offerings
by Zacks Equity Research
Veeva Systems (VEEV) continues to boost its cloud-based offerings profile with the adoption of Vault PromoMats by Bristol Myers.
Here's Why You Should Invest in Cardinal Health (CAH) Stock
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment, diversified product portfolio and strategic buyouts.
LHC Group (LHCG) Forays into Oklahoma With New Hospice Buyout
by Zacks Equity Research
LHC Group (LHCG) buys Grace Hospice of Oklahoma to expand its hospice service to Tulsa and throughout the nation.
Here's Why You Should Retain Stryker (SYK) Stock Right Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in its robotic-arm assisted surgery platform - Mako and broad product portfolio. However, pricing pressure raises concern.
PerkinElmer's Non-Invasive Saliva-Based Testing Gets CE Mark
by Zacks Equity Research
PerkinElmer's (PKI) new saliva-based collection and asymptomatic test solution receives CE-IVD mark.
Why Cardinal Health (CAH) is Such a Great Value Stock Pick Right Now
by Zacks Equity Research
Cardinal Health (CAH) seems to be a good value pick, as it has decent revenue metrics to back up its earnings, and is seeing solid earnings estimate revisions as well.
Here's Why You Should Retain McKesson (MCK) Stock for Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from multi-year strategic growth initiative and Distribution Solutions segment.
CAH vs. ALGN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CAH vs. ALGN: Which Stock Is the Better Value Option?
Has Cardinal Health (CAH) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (CAH) Outperforming Other Medical Stocks This Year?
Stock Market News for Nov 6, 2020
by Zacks Equity Research
U.S. stock markets closed sharply higher on Thursday as the wait for the U.S. Presidential election outcome continues.
Cardinal Health (CAH) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Cardinal Health's (CAH) fiscal first-quarter results reflect strong segmental performance.
Cardinal Health (CAH) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Cardinal (CAH) delivered earnings and revenue surprises of 32.46% and 1.68%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Cigna (CI) Maintain Its Beat Streak in Q3 Earnings?
by Zacks Equity Research
Cigna's (CI) Q3 results are likely to reflect revenue growth owing to a strong fundamental performance. Earnings, however, might have been affected by steep medical costs from moderation in deferment of care related to the COVID-19 pandemic.
Should You Buy Cardinal Health (CAH) Ahead of Earnings?
by Zacks Equity Research
Cardinal Health (CAH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Medical Products' Nov 5 Earnings Roster: BDX, ABC & More
by Trina Mukherjee
Medical Product companies have shown strength in the third quarter on the back of huge adoption of COVID-19 related healthcare-support products and services despite the impact of the ongoing pandemic.
Cardinal Health (CAH) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) fiscal first-quarter results are likely to reflect solid performance in Pharmaceutical segment.
DENTSPLY SIRONA (XRAY) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) third-quarter results are likely to reflect weak segmental performance.
AmerisourceBergen (ABC) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal fourth-quarter results are likely to reflect solid performance at Pharmaceutical Distribution and Other units.
Invitae (NVTA) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Invitae's (NVTA) genetic testing business is expected to have gained from expansion of biopharma partnerships in Q3.
Cardinal Health (CAH) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Cardinal (CAH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Dental Supplies Stocks Set to Shine on the Industry's Upturn
by Trina Mukherjee
Despite the challenges thrown by the COVID-19 pandemic, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical - Dental Supplies industry. CAH, WST and MCK are well positioned to gain from the prospects.
Henry Schein (HSIC) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Henry Schein's (HSIC) medical business' PPE sales are likely to have maintained its momentum along with global recovery trends of the dental business during Q3.
ABIOMED (ABMD) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
The full commercial launch of Impella 5.5 in May is expected to have contributed to ABIOMED's (ABMD) fiscal second-quarter results
Quidel (QDEL) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Quidel (QDEL) is likely to have witnessed an uptick in rapid immunoassay revenues in Q3.